Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Actinium Pharmaceuticals (DE:7AY1)
FRANKFURT:7AY1
RESEARCH TOOLSreports
Actinium Pharmaceuticals (7AY1) Stock Price & Analysis
0 Followers
7AY1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€3.60 - €8.67
Previous Close€6.79
Volume0.00
Average Volume (3M)885.00
Market Cap
€216.25M
Enterprise Value€146.66M
Total Cash (Recent Filing)$84.06M
Total Debt (Recent Filing)$9.49M
Price to Earnings (P/E)N/A
Beta0.48
Next Earnings
Mar 14, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding29,783,451
10 Day Avg. Volume180
30 Day Avg. Volume885
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)5.28
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.81K
Enterprise Value/Gross Profit1.81K
Enterprise Value/Ebitda-4.89
Forecast
1Y Price Target
€28.41Price Target Upside297.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Actinium Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Acquisition And Industry TrendsNovartis' acquisition of Mariana Oncology enhances its radiotherapy offerings, signaling broader industry confidence in the potential of radiotherapeutic technologies.
Clinical Trial ResultsSubgroup analysis of Iomab-B from the SIERRA trial shows remarkable long-term survival rates for patients over 65 with AML, indicating a significant advance in treatment options.
Strategic InitiativesActinium's strategic investment in cyclotron-based Ac-225 isotope production could lead to more affordable and reliable supply, potentially offering a new revenue stream and bolstering its position in radioisotope therapy.
Bears Say
Financial PerformanceActinium filed its 10-K, reporting 4Q23 results with a net loss of ($48.8M).
Market OutlookPatients over 65 years old face a challenging outlook, often making allo-HCT less feasible due to increased non-relapse mortality and existing health issues.
Product LaunchThe price target for Actinium Pharmaceuticals has been lowered from $20 to $16 due to a delayed commercial launch of Iomab-B.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.00% Mutual Funds
0.08% Other Institutional Investors
99.92% Public Companies and
Individual Investors
7AY1 FAQ
What was Actinium Pharmaceuticals’s price range in the past 12 months?
Actinium Pharmaceuticals lowest stock price was €3.60 and its highest was €8.67 in the past 12 months.
What is Actinium Pharmaceuticals’s market cap?
Currently, no data Available
When is Actinium Pharmaceuticals’s upcoming earnings report date?
Actinium Pharmaceuticals’s upcoming earnings report date is Mar 14, 2025 which is in 313 days.
How were Actinium Pharmaceuticals’s earnings last quarter?
Actinium Pharmaceuticals released its earnings results on Mar 15, 2024. The company reported -€0.317 earnings per share for the quarter, beating the consensus estimate of -€0.532 by €0.215.
Is Actinium Pharmaceuticals overvalued?
According to Wall Street analysts Actinium Pharmaceuticals’s price is currently Undervalued.
Does Actinium Pharmaceuticals pay dividends?
Actinium Pharmaceuticals does not currently pay dividends.
What is Actinium Pharmaceuticals’s EPS estimate?
Actinium Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Actinium Pharmaceuticals have?
Currently, no data Available
What happened to Actinium Pharmaceuticals’s price movement after its last earnings report?
Actinium Pharmaceuticals reported an EPS of -€0.317 in its last earnings report, beating expectations of -€0.532. Following the earnings report the stock price went down -5.738%.
Which hedge fund is a major shareholder of Actinium Pharmaceuticals?
Among the largest hedge funds holding Actinium Pharmaceuticals’s share is Royce & Associates LLC. It holds Actinium Pharmaceuticals’s shares valued at 254K.
---
Actinium Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€28.41 (297.29% Upside)
€28.41 (297.29% Upside)
Blogger Sentiment
Bullish
DE:7AY1 Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.10%
12-Months-Change
Fundamentals
Return on Equity
-91.92%
Trailing 12-Months
Asset Growth
-13.40%
Trailing 12-Months
Company Description
Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.
---
7AY1 Stock 12 Months Forecast
Average Price Target
€28.41
▲(297.29% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
Aptose Biosciences
―
Celldex
―
Cyclacel Pharmaceuticals
―
Kura Oncology
―
Best Analysts Covering 7AY1
1 Year
1 Year Success Rate
9/14 ratings generated profit
1 Year Average Return
+12.12%
reiterated a buy rating 3 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +12.12% per trade.
---